Janssen says Phase 3 data demonstrate superiority of Tremfya vs. Consentyx.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the ECLIPSE study demonstrating that Tremfya was superior to Cosentyx in treating adults with moderate to severe plaque psoriasis for the primary endpoint assessed at week 48. Data from the multicenter, randomized, double-blind head-to-head Phase 3 study demonstrated that 84.5% of patients treated with guselkumab achieved at least 90% improvement in their baseline Psoriasis Area Severity Index score at week 48, compared with 70.0% of patients treated with secukinumab. "These data, presented at the 3rd Inflammatory Skin Disease Summit in Vienna, 12-15 December, mark the first-ever results from a head-to-head study comparing an interleukin (IL)-23-targeted biologic therapy with an IL-17 inhibitor. ECLIPSE is Janssen's fourth Phase 3 study for guselkumab in plaque psoriasis2-4 and is part of a comprehensive clinical development program that also includes ongoing Phase 3 studies in psoriatic arthritis and Crohn's disease," the company stated.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Clinical report|
|Date:||Dec 12, 2018|
|Previous Article:||Fed Policy Outlook: the FOMC remains on course for a 25 bp December 19 rate hike.|
|Next Article:||Enterprise Holdings, GM partner to add 100,000 connected cars in 2019.|